Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders, characterized by ineffective hematopoiesis, a variable degree of cytopenia, and an increased risk for developing acute myelogenous leukemia (AML) [1] . MDS with ≥ 2% blasts in PB or ≥ 5% but less than 20% blasts in the BM is classified as MDS-EB in the most recent WHO classification of myeloid neoplasms [2] .
the region has highlighted better outcome in younger patients [13] . We conducted a retrospective observational study to review the outcome of HCT in pediatric patients with MDS treated at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Patients and methods
A group of 35 transplant naïve pediatric patients (age ≤ 14 years at diagnosis) with MDS who underwent HCT at our institution from Jan 1993 to December 2016 were identified. A total of 37 patients were transplanted in allogeneic fashion from Jan 1993 to December 2016 at our institution. Two (2) were excluded for having previously been transplanted at other hospitals. Data on demographics, diagnosis, transplant-related parameters and outcome were extracted from prospectively maintained clinical databases and through medical charts review. After quality assurance checks, the dataset was then transferred to IBM-SPSS for Windows Version 20.0 for final analyses. 
Results
With a median follow-up time of 112.4±31.7 months, the cumulative probability of five-year overall survival (OS) was 64.5%±8.3% for the whole cohort, 67.1%±9.7% for LR and 55.6%±16.6% for HR MDS patients respectively (p-value: 0.530, Fig. 1 ). The probability of fiveyear overall survival same was 72.7%±13.4% in the sub-group of patients with age at transplant between 5-10 years as compared to 66.7%±27.2% in those with over 10 years followed by 60.5%±10.9%
who were transplanted in the first five years of their life. However, this difference did not achieve statistical significance (table II) . Event Free survival (EFS) for our patients in this study was 64.5%±8.3%. Based on chimerism studies, 93.9% (31) of evaluable patients (alive) have been engrafted, while among the remaining, one was never engrafted and the other patient, was engrafted and then had a failed graft.
Based on chimerism studies, all those patients alive at Day-100 (n = 29) were fully engrafted; 21 (72.4%) were from LR and eight (27.6%) from HR MDS. Among those at risk (n = 29) beyond Day-100, three patients expired from each risk group as engrafted, thus making our mortality count of twelve at the time of this review.
Cumulative incidence of acute graft versus host disease (aGvHD) was 37.1% (13) (9) instances of skin a GvHD while seven (7) instances of the same were seen for the gut. No hepatic a GvHD was observed in our group of patients. No secondary malignancy was recorded in our cohort of patients while on follow-up. At the last update, all surviving patients were maintaining sustained donor chimerism.
Discussion
Allogeneic HCT currently offers the best chance of cure and longterm survival for children with advanced MDS [14, 15] . In this article, we reported the outcome of pediatric patients with MDS treated with allogeneic HCT at a single institution. To study a more homogeneous cohort of patients, and in compliance with the recent WHO classification, we excluded patients with secondary MDS (treatment related MDS, and MDS secondary to inborn bone marrow failure syndromes) from this analysis. Myeloablative regimen was used for all of our patients, while for 51.4% it was Bu/Cy /VP-16. The safety profile of etoposide as part of the conditioning regimen has been widely explored in adult studies [16] . In children, however, few studies have addressed the use of high-dose etoposide (40-60 mg/kg) in combination with other agents in the preparative regimens with a lower dose of Bu/Cy. In our study, VP-16 was well tolerated and had less toxicity with no increased incidence of GvHD or VOD. This finding is comparable with previous study from the same center by
Al-Seraihy et al [13] . Late complication of etoposide like secondary malignancy especially AML was not noted in our study. Three-year OS and EFS of our cohort of patients was 0.681±0.080. The probability of five-year overall survival was 0.727±0.134 in the sub-group of patients with age at transplant between 5-10 years as compared to 0.667±0.272 in those with over 10 years followed by 0.605±0.109 who were transplanted in first five years of their life. Historically, HCT with a myeloablative regimen has been reported with an EFS of 75% with TRM being the major cause of treatment failure [17] . 5-year probability of EFS after the first allograft is 59% (49-69) [6] .
In view of these findings, reduced-intensity conditioning might be an attractive approach at least for patients with hypocellular marrow and normal karyotype [18, 19] . In a pilot study conducted in nineteen children treated at centers affiliated with EWOG-MDS, HCT after a preparative regimen that includes thiotepa and fludarabine resulted in a probability of OS of 84% and an EFS reaching 74% [19] . These toxicity [21, 25, 26] . Therefore, the role of intensive chemotherapy before HCT for patients with advanced MDS has remained a matter of debate. In this Study, the use of pre-transplant chemotherapy pretransplant did not seem to improve the EFS or the outcome, although, the small sample size of our study and only 2 patients received chemo may be enabled to conduct comparative analysis. We were unable to do any comparative analysis in this regard as only two patients were treated with pre-transplant chemotherapy in our cohort.
Relapse has been a major contributor to mortality in pediatric patients, with a statistically significant higher relapse rate in MDS-EB and MDS-EB-t cases as compared to RC. In this regard, report from AlSeraihy et al showed no correlation between relapse rate and MDS classification, which was comparable to other studies [13] . In addition to graft failure, infections secondary to immunosuppression from GvHD and its therapy were a major cause of non-relapse mortality in our patients, as shown in other series [25, 26, 27] Donor type has always been considered as a major factor influencing the outcome following allogeneic HCT. Studies specifically addressing the role of HCT in children with MDS have indicated a probability of an EFS of about 50% following transplant with an HLA-matched family donor [25, 26] , the same as obtained similar to what was observed in our series. The use of unrelated BM donors was associated with a higher incidence of acute and chronic GvHD, a higher transplant related mortality, and EFS probability of around 29% [28, 29] .
Parikh et al [24] reported encouraging data regarding the use of UCB as a stem cell source for children with primary and secondary MDS achieving a three-year EFS of 60.9%, with a lower incidence of acute and chronic GVHD.
Conclusion
Although etoposide based conditioning was observed to be well tolerated yet, the Bu/Cy/±ATG conditioning regimen showed a trend of superiority for OS and EFS in our small series of patients undergoing HCT for MDS. The relapse incidence in our cohort was 11.5% in LR MDS group.
